%0 Journal Article
%T Bax promoter G(£248)A polymorphism in a Turkish clinical breast cancer patients: A case-control study
%A Yemliha Yildiz
%A Ilhan Yaylim
%A Nazli Ezgi Ozkan
%A Soykan Arikan
%A Saime Turan
%A Seden Kucucuk
%A Ender Coskunpinar
%A Turgay Isbir
%J American Journal of Molecular Biology
%P 10-16
%@ 2161-6663
%D 2013
%I Scientific Research Publishing
%R 10.4236/ajmb.2013.31002
%X Bax is an important protein involved in apoptotic process. Mutations of the Bax gene are known to af- fect protein expression and function. A promotor polymorphism G(£248)A in the 5¡¯UTR of Bax gene may alter regulation of apoptosis in carcinogenesis. Our study was performed to test the association be- tween G(£248)A polymorphisms in the Bax gene and breast cancer risk and progression. G(£248)A poly- morphism was genotyped in a Turkish breast cancer, case-control population including 53 female cancer patients (mean age ¡À SD: 60.9 ¡À 11.9 years) and 82 controls (mean age ¡À SD: 57.2 ¡À 17.5 years) using PCR-RFLP analysis. Genotype and allele frequencies were assessed with the chi-square test. There was no difference in the distribution of Bax genotypes, and allele frequencies were G (87.7% versus 88.4%) and A (12.3% versus 11.6%) in the cancer patients and controls, respectively. Within the cancer group, the presence of a polymorphic Bax G(£248)A allele was not associated with clinico-pathological parameters such as advanced tumor stage, lymph node or distant metastasis. We present the first to report on Bax G(£248)A polymorphisms in breast cancer. Our re- sults suggest that Bax G(£248)A polymorphism do not modify individual susceptibility to invasive breast cancer in Turkish women.
%K Bcl-2 Associated-X-Protein
%K SNP
%K Apoptosis
%K PCR
%K Susceptibility
%K Carcinogenesis
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=26993